Elsevier Introduces Reaxys Xcelerate™

A new premium version of Reaxys® for research intensive institutions

Frankfurt, Germany, January 30, 2012 – Elsevier, a world-leading provider of scientific, technical and medical information products and services, today announced the launch of Reaxys Xcelerate™, a premium version of Reaxys® developed in close consultation with research intensive organizations. Reaxys Xcelerate™ further extends the capabilities of Reaxys®, a leading workflow solution that provides extensive information on chemical compounds and reactions.

Reaxys Xcelerate™ has been designed to streamline research intensive chemistry workflows for:

“Working closely with our partners, we identified and invested in a number of new tools to support research intensive workflows,” said Mark van Mierle, Managing Director of Elsevier’s Pharma and Biotech Group. “For organizations in competitive research environments, whether at corporations developing new materials, pharmaceutical organizations developing potential drugs, or academic institutions conducting groundbreaking research Reaxys Xcelerate™ provides a step change in individual and organizational productivity.”

Reaxys ® and Reaxys Xcelerate™ follow the same agile development process, ensuring that the two versions continue to deliver the relevant content and insights needed by research chemists. To find out more about Reaxys Xcelerate™, including the opportunity to experience the product, visit www.reaxys.com/info/xcelerate.

Reaxys ® and the Reaxys trademark are owned and protected by Elsevier Properties SA and used under license.

About Elsevier

Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Elsevier Research Intelligence,and ClinicalKey—and publishes over 2,200 journals, including The Lancet and Cell, and over 33,000 book titles, including a number of iconic reference works.

The company is part of Reed Elsevier Group PLC, a world leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).

Media contact
Tom Reller
Vice President, Global Corporate Relations, Elsevier
+1 215 239 3508